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Background: Preventive nebulization of mucolytic agents and bronchodilating drugs is a strategy aimed at the
prevention of sputum plugging, and therefore atelectasis and pneumonia, in intubated and ventilated intensive
care unit (ICU) patients. The present trial aims to compare a strategy using the preventive nebulization of
acetylcysteine and salbutamol with nebulization on indication in intubated and ventilated ICU patients.
Methods/Design: The preventive nebulization of mucolytic agents and bronchodilating drugs in invasively ventilated
intensive care unit patients (NEBULAE) trial is a national multicenter open-label, two-armed, randomized controlled
non-inferiority trial in the Netherlands. Nine hundred and fifty intubated and ventilated ICU patients with an
anticipated duration of invasive ventilation of more than 24 hours will be randomly assigned to receive either a
strategy consisting of preventive nebulization of acetylcysteine and salbutamol or a strategy consisting of nebulization
of acetylcysteine and/or salbutamol on indication. The primary endpoint is the number of ventilator-free days and
surviving on day 28. Secondary endpoints include ICU and hospital length of stay, ICU and hospital mortality, the
occurrence of predefined pulmonary complications (acute respiratory distress syndrome, pneumonia, large atelectasis
and pneumothorax), and the occurrence of predefined side effects of the intervention. Related healthcare costs will be
estimated in a cost-benefit and budget-impact analysis.
Discussion: The NEBULAE trial is the first randomized controlled trial powered to investigate whether preventive
nebulization of acetylcysteine and salbutamol shortens the duration of ventilation in critically ill patients.
Trial registration: NCT02159196, registered on 6 June 2014.
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Preventive nebulization of mucolytic agents and bronch-
odilating drugs is a strategy aimed at the prevention of
airway obstruction in intubated and ventilated intensive
care unit (ICU) patients [1–3]. This strategy was intro-
duced in the 1990s [1, 2, 4], when it was recognized that
invasively ventilated ICU patients are frequently unable
to cough adequately, potentially resulting in stasis of
sputum in the larger and smaller airways [5–7]. This
could lead to clinically important atelectasis [8] and
ventilator-associated pneumonia [9]. Preventive nebuli-
zation of mucolytic agents like acetylcysteine could, at
least in part, solve this problem. As nebulization would
dilute pulmonary secretions [10], it might be easier for a
patient to evacuate secretions to the larger airways ready
to be suctioned. As local application of acetylcysteine in-
duces bronchospasm, traditionally a bronchodilating
drug was added [1, 2, 11], with the additional advantage
that bronchodilators like salbutamol augment mucocili-
ary clearance [7].
Practices of nebulization during mechanical ventilation
are known to be diverse, as evidence of a beneficial effect
is limited and inconclusive [1, 2, 4, 12, 13]. In addition,
care for the invasively ventilated ICU patient has changed
significantly over the last decades. The commonly used
practice of (deep) hypno-sedation and paralysis has been
replaced by analgo-sedation with the restricted use of
neuromuscular blocking agents [14], and ventilated ICU
patients are mobilized more frequently and early during
the course of their disease [15]. These changes in care
may have resulted in an increased ability of invasively ven-
tilated ICU patients to clear their airways. Consequently,
this may render preventive nebulization of mucolytic
agents and bronchodilating drugs an ineffective and un-
needed strategy during mechanical ventilation. This may
be especially true because nebulization of mucolytic agents
and bronchodilating drugs carries the risk of local
and systemic side effects, such as acetylcysteine-
induced bronchoconstriction [1, 16, 17], and salbutamol-
induced tachycardia and tachy-arrhythmias [18–20]. Also,
nebulization could temporarily hamper triggering of the
ventilator by a patient, potentially causing hypoventilation
and patient distress [21].
The aim of the present trial is to determine the efficacy
and safety of a strategy using preventive nebulization of
acetylcysteine and salbutamol compared to a strategy using
nebulization on indication in intubated and ventilated ICU
patients. Furthermore, the related healthcare costs of this
preventive strategy are determined. We hypothesize that a
strategy using nebulization on indication in invasively venti-
lated ICU patients is not inferior with regard to the number
of ventilator-free days and survival to day 28, but is associ-
ated with fewer side effects and lower health-related costs,
compared to a strategy using preventive nebulization.Methods/Design
Design
This randomized controlled trial investigating the (cost-)
effectiveness and safety of preventive nebulization of mu-
colytic agents and bronchodilating drugs in intubated and
ventilated ICU patients, called the NEBULAE trial, is an
investigator-initiated, national, multicenter, randomized
controlled, open-label, two-armed non-inferiority trial in
invasively ventilated patients admitted to participating
ICUs in the Netherlands.
Trial approval and conduct
The trial is conducted according to the principles of the
Declaration of Helsinki as stated in the current version
of Fortaleza, Brazil, October 2013 [22], the Dutch law of
Medical Research Involving Human Subjects (WMO)
and Good Clinical Practice Guidelines (GCP). The trial
protocol is approved by the Institutional Review Board
of the Academic Medical Center, Amsterdam, The
Netherlands and reviewed for local feasibility by the
Institutional Review Boards of all participating medical
centers represented in Additional file 1. The trial is reg-
istered at www.clinicaltrials.gov (NCT02159196) and at
www.trialregister.nl (NTR4465). The trial is supported in
full by a peer-reviewed grant from ZonMW, Netherlands
Organization for Health Research and Development
[23], which provided constructive comments on the trial
design. ZonMW is not involved in the process of data
collection, data analysis, data interpretation, and writing
of the report. Written informed consent has to be given
by the patient or their legal representative before any
trial related procedure is performed. The trial will be
reported according to the Consolidated Standards of
Reporting Trials (CONSORT) guidelines [24].
CONSORT diagram
The CONSORT [25] diagram of the NEBULAE trial is
presented in Fig. 1. Screening of consecutive patients
admitted to one of the participating ICUs to verify the
source population and conformance with enrolment
criteria will be performed by the local investigators in all
participating centers. The trial plan is to include 950
patients. If patients are excluded from participation, the
reason(s) for exclusion are registered.
Setting
The trial is performed in at least seven ICUs, one in a
university-affiliated hospital (the Academic Medical Cen-
ter, Amsterdam) and six in teaching hospitals (Rijnstate
Hospital, Arnhem; Onze Lieve Vrouwe Gasthuis,
Amsterdam; Amphia Hospital, Breda, Oosterhout and
Ettenleur; Antonius Hospital, Nieuwegein; Medical
Center Haaglanden, The Hague and Leidschendam; and
Isala Hospital, Zwolle) in the Netherlands.
Randomization – stratified per center
950 patients
Allocated to preventive 
nebulization*
475 patients 
Excluded (n=  )
- Exclusion criteria (n=  )
- Declined to participate (n=  )
- Other reason (n=  )






















Per protocol (PP) analysis2 (n=  )







Follow up  day 28 & 90
Assessed for eligibility (n=  )
Excluded from per protocol analysis (n= )
- Protocol discontinuation, specified (n= ) 
- Protocol violation, specified (n= )
- Other reason, specified (n= ) 
Excluded from analysis (n= )
- Lost to follow up, specified (n= )
- Withdrew consent, specified (n= )
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT)
diagram. *Until successful extubation; ** From day 1 until
extubation, death or day 28 if still intubated, whichever comes first;
1Including all patients as originally allocated after randomization;
2Including only those patients who completed the treatment
protocol as originally allocated
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Invasively ventilated adult nonpregnant patients, aged ≥18
years, with an anticipated duration of ventilation of more
than 24 hours, are eligible for participation. Patients are
excluded if they received invasive ventilation in another
ICU directly preceding the present ICU admission; venti-
lation during transport to the hospital, or ventilation
started in the emergency room or in the operating theater
is allowed though. In cases where the medical history ne-
cessitates the continuation of bronchodilators (for ex-
ample, for chronic obstructive pulmonary disease or
asthma) or in cases of a known allergy to the trial medica-
tion, the patient will be excluded from participation.Patients with neuromuscular diseases or complete spinal
cord lesions, and consequently with an expected need for
long-term ventilation, are also excluded. Finally, previous
randomization in the NEBULAE trial excludes patients
from participation as well.
Patient enrollment, randomization and blinding
Consecutive patients are screened for eligibility by local
investigators and treating physicians. Patients meeting all
inclusion criteria and no exclusion criteria are candidates
for inclusion in the study and will be randomly assigned
in a 1 to 1 ratio, after informed consent is given by the pa-
tient or their legal representative, to either a strategy of
preventive nebulization of acetylcysteine and salbutamol
four times daily (the ‘preventive nebulization’ arm) or neb-
ulization of acetylcysteine or salbutamol on indication
(the ‘nebulization on indication’ arm). Randomization will
be performed by the local investigators and treating physi-
cians as soon as possible, but always within 24 hours after
start of invasive ventilation in the ICU. To avoid predic-
tion of future patients’ allocation, randomization sequence
is generated using a permuted block design with random
block sizes stratified by study center. Maintenance of allo-
cation concealment will be warranted using a central, ded-
icated, password-protected, SSL-encrypted web-based,
automated randomization system, available 24 hours per
day (ALEA® software, TenALEA consortium, Amsterdam,
The Netherlands), developed by the Clinical Research
Unit in the Academic Medical Center, Amsterdam, The
Netherlands, which is not involved in the conduct of the
study. Due to the nature of the intervention, blinding of
the patients and caregivers is not possible. Outcomes as-
sessment will be performed according to the study proto-
col by independent ICU physicians not involved in the
trial. Investigators performing analysis are blinded for the
intervention.
The assigned strategy is continued until tracheal extu-
bation. If a patient requires reintubation and additional
invasive ventilation within a period of 28 days, the strat-
egy to which the patient is randomized will be resumed.
Interventions
When randomized to the preventive nebulization arm,
the patient will receive nebulization every 6 hours with
solutions containing 300 mg acetylcysteine plus 2.5 mg
salbutamol. Flasks of acetylcysteine and salbutamol are
provided by the pharmacy of the participating center.
Since no placebo will be used, labeling of the drugs is
not necessary. Solutions are nebulized using jet nebu-
lizers or vibrating mesh nebulizers, depending on local
availability in the participating centers. Nebulizers are
set according to manufacturer’s recommendations. Ex-
ternal nebulizers are powered by pressured air or oxy-
gen at a continuous flow of 3 to 5 L/min. The nebulizer
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heated humidifier or the heat and moisture exchange
(HME) filter (that is, at the side of the patient). A nebu-
lization session typically lasts 20 to 30 minutes. The
type of nebulizer used will be recorded in the case rec-
ord form (CRF).
When randomized to the nebulization on indication
arm, nebulization of acetylcysteine or salbutamol is re-
stricted. The doctor staff can decide to order nebuliza-
tion of solutions containing 300 mg acetylcysteine or 2.5
mg salbutamol in case a patient has persistent thick and
tenacious secretions [26] or in cases of bronchospasm
(suspected when there is a clinical wheezing, and signs
of obstruction of the lower airways on ventilator waves
or the end-tidal CO2 curve), respectively. Daily reassess-
ment of the indications mentioned above will reassure
that nebulization is stopped when no longer needed.
The decision to start and stop nebulization is recorded
in the CRF.
Concomitant medications
Mucolytic agents or bronchodilating drugs other than
acetylcysteine and salbutamol are not used. Nebulization
of drugs other than mucolytic agents or bronchodilating
drugs (for example, antimicrobial and antimycotic
agents, or ilomedine and iloprost) however, remains pos-
sible. They should be administered separately from the
nebulization of acetylcysteine and salbutamol and re-
corded in the CRF.
Standard lung protective care
Standard care follows the local clinical guidelines and is
performed by independent ICU physicians and nurses
not involved in the trial. Doctor and nursing staff are en-
couraged to use lung-protective ventilation strategies, in-
cluding the use of lower tidal volumes; restrictive
sedation; early weaning, preferably by the use of weaning
trials; fluid restriction; and infection prevention.
Lung-protection includes the use of lower tidal vol-
umes (6 ml/kg predicted body weight, in patients with
ARDS [27, 28], as well as in patients without ARDS
[29]); higher levels of positive end-expiratory pressures
(>5 cm H2O) are only used in cases of suspected shunt-
ing or signs of moderate or severe ARDS [30, 31].
Restrictive sedation includes the use of a local sed-
ation guideline aiming at analgo-sedation and prevent-
ing hypno-sedation [32, 33], with a preference for
intermittent sedation over continuous infusion of seda-
tives [34]; sedation depth is evaluated at least three
times a day using the Richmond Agitation Sedation
Scale (RASS) [35, 36]; pain is scored using the Numeric
Rating Scale (NRS), Visual Analog Scale (VAS), Critical
Care Pain Observation Tool (CCPOT) or Behavioral Pain
Scale (BPS), and treated accordingly [37–39]. Delirium isassessed at least three times daily using a standardized
tool, that is, the Confusion Assessment Method for the
ICU (CAM-ICU) or the Intensive Care Delirium Checklist
Screening (ICDCS) [40].
Doctor and nursing staff are encouraged to frequently
test whether a patient triggers the ventilator and, if so, to
use spontaneous modes of ventilation. Readiness to wean
will be assessed on a daily basis. Pressure–support level is
lowered stepwise to 5 cm H2O, as soon as patients are
ready to be weaned from the ventilator. Attending physi-
cians will decide to extubate the patient, based on general
extubation criteria (for example, patient is responsive and
cooperative with an adequate cough reflex, an adequate
oxygenation saturation (>90 %) with PaO2/FiO2 of >200
mmHg and FiO2 ≤40 % and a respiratory rate of 8 to 30
per minute with no signs of respiratory distress (that is,
marked accessory muscle use, abdominal paradox, dia-
phoresis, or marked dyspnea), is hemodynamically stable
with no uncontrolled arrhythmia, and has a rectal
temperature >36.0°C).
Fluid management follows the local guidelines and is
dictated by clinical needs but aims at a neutral fluid bal-
ance as soon as possible after stabilization and weaning
of inotropes and/or vasopressors [41]. Crystalloid infu-
sions are favored over colloid infusions [42]. Transfusion
of blood products is restricted.
Infection prevention consists of oral care, combining
tooth brushing and rinsing of the oral cavity every 6
hours, and selective oropharyngeal decontamination or
selective decontamination of the digestive tract are ap-
plied to all patients according to local clinical guidelines
to prevent nosocomial infections [43]. Head-of-bed ele-
vation is pursued [44]. Ventilator circuits are not chan-
ged routinely unless a circuit is visibly contaminated or
damaged [45].
Standard airway care
Independent ICU physicians and nurses not involved in
the trial perform standard airway care, including endo-
tracheal suctioning, humidification of inhaled air and
tracheostomy placement.
Endotracheal suction is performed when clinically in-
dicated and according to the local guidelines [46]. Nor-
mal saline instillation prior to endotracheal suction will
not be used [46]. The use of an open or closed endo-
tracheal suction system is left to the discretion of the
participating center and will be recorded in the CRF.
Humidification and heating method of the inhaled air
is left to the discretion of the participating center and
will be recorded in the CRF. Active humidification of the
air inhaled will be supplied by the use of an electrically
powered humidifier. Passive humidification of the air in-
haled will be supplied by the use of a heat and moisture
exchange filter.
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preferably not in the first ten days after intubation [47]. In-
dications for tracheostomy are failure to intubate, expected
duration of ventilation >14 days, Glasgow Coma Score <7
and/or inadequate swallow or cough reflex with retention
of sputum, severe ICU acquired weakness, prolonged or
unsuccessful weaning and repeated respiratory failure after
tracheal extubation.
Primary outcome and secondary outcomes of the trial
The primary outcome of this study is the number of
ventilator-free days (VFD) and survival to day 28, de-
fined as the number of calendar days of unassisted
breathing, after both ICU admission and start of
mechanical ventilation to day 28, if the period of un-
assisted breathing lasted at least 24 consecutive hours.
Unassisted breathing is defined as being extubated,
ventilating with or without facemask, nasal prong
oxygen, room air or tracheostomy breathing, but al-
ways without continuous positive airway pressure or
pressure support of intermittent mandatory ventilation as-
sistance. Patients who die before 28 days or are mechanic-
ally ventilated longer than 28 days are assigned zero
ventilator-free days.
Secondary outcomes include clinical endpoints and
cost-effectiveness outcomes. Clinical endpoints include
the following: ICU and hospital length of stay (LOS);
ICU, hospital, and 90-day mortality; development of
moderate or severe ARDS; ventilator-associated pneu-
monia (VAP); development of atelectasis and pneumo-
thorax; incidence of obstruction of the endotracheal
tube (wherefore endotracheal tube exchange is indis-
pensable); cumulative dose and duration of sedatives, cu-
mulative dose and duration of neuromuscular blocking
agents, development of delirium and incidence of side
effects of nebulization of acetylcysteine and/or salbuta-
mol. In addition, related healthcare costs will be com-
pared from a health systems perspective over the time
horizon of the trial and include direct medical and indir-
ect costs of days of mechanical ventilation, stay in the
ICU and hospital, cumulative use of sedatives and
neuromuscular blocking agents, tracheostomies and
ventilator-associated pneumonia.
Clinical data to be collected
Data on baseline, demographic characteristics and disease
severity are collected on the day of enrolment, including
gender, age, height, weight, reason for ICU admission, rea-
son for invasive mechanical ventilation and the APACHE
II score. Furthermore, data are collected on the medical
history including presence of diabetes mellitus, severe
heart failure (New York Heart Association NYHA classifi-
cation) [48], acute coronary syndrome or pulmonary dis-
ease, pulmonary or hematological malignancies, previouspulmonary radiation and/or surgery, and current use of
immunosuppressive medication.
Data on clinical outcomes are collected on a daily
basis up to day 28, discharge of the ICU or death, in-
cluding data on duration of ventilation, length of stay in
ICU and hospital. Location of the patient (ICU, hospital,
other facility, or home) and life status (alive or deceased)
is assessed on days 28 and 90.
Clinical data are collected on a daily basis up to day
28, discharge from the ICU or death, and these data
include: intubation status (if extubated: time of extu-
bation), tracheostomy status, mechanical ventilation
parameters (see below), development of pulmonary com-
plications (moderate or severe ARDS, pneumonia, atel-
ectasis and pneumothorax); cumulative use and duration
of sedatives and neuromuscular blocking agents; sed-
ation score using the Richmond Agitation Sedation Scale
(RASS) [35, 36]; level of pain (Numeric Rating Scale or
Visual Analog Scale or Critical Care Pain Observation
Tool or Behavioral Pain Scale) [37–39]; delirium score
with the Confusion Assessment Method for ICU (CAM-
ICU) or Intensive Care Delirium Checklist Screening
(ICDCS) [40] score; amount and type of infused blood
products; cumulative fluid balance and Sequential Organ
Failure Assessment (SOFA) [49].
Parameters of mechanical ventilation are collected 1
hour after intubation and every day at a fixed time point
up until extubation, day 28 or death including the follow-
ing: tidal volume, respiratory rate, levels of PEEP, Ppeak
and/or Pplateau, the level of pressure support, inspiration
to expiration ratio, oxygen fraction of inspired air, minute
volume and pulmonary compliance. The Lung Injury
Score [50] and Oxygenation Index [51] are calculated.
Compliance data are collected on a daily basis until
extubation up to day 28 or death, including the quantity
of secretions, type of humidifier (active or passive),
amount and indication of nebulization of acetylcysteine
and/or salbutamol, episodes of nebulization of other
agents and side effects of nebulization of acetylcysteïne
and/or salbutamol.
Resource-use parameters and unit prices are collected
to estimate healthcare costs from a health systems per-
spective and include the medical costs of ventilation,
ICU stay, in hospital stay, cumulative use of sedatives
and neuromuscular blocking agents, tracheostomies and
ventilator-associated pneumonia.
Sample size calculation
Randomized trials assessing the efficacy of preventive neb-
ulization are absent, which hampered power calculations.
Therefore, the sample size calculation, based on a non-
inferiority design, is calculated using the mean duration of
invasive ventilation and the associated coefficient of vari-
ation, respectively 5 and 0.7 (log-transformed data) days
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difference in clinical effectiveness of 10 % between the
‘nebulization on indication’ arm as compared to the ‘pre-
ventive nebulization’ arm will be tolerated to consider a
strategy of ‘nebulization on indication’ not to be inferior,
with regard to the primary endpoint ventilator free days.
Using these assumptions associated with the study design,
a one-sided type I error of 0.05 and 80 % power (type II
error), yields a sample size of 950 patients, which includes
a 5 % anticipated drop out.
Interim analysis
Interim analyses regarding safety are performed by an
independent Data Safety Monitoring Board (DSMB)
when 317 and 634 patients, have been included and have
completed follow-up for the primary outcome. These in-
terim analyses are not related to the non-inferiority
hypothesis.
Data analysis
The main analysis will compare the number of ventilator-
free days and survival to day 28 between the two ran-
domized groups. If the non inferiority of nebulization
on indication compared to preventive nebulization can
be confirmed, the superiority of nebulization on indica-
tion compared to preventive nebulization for the pri-
mary endpoint will be tested.
In addition, we will analyze the non inferiority between
the two treatment groups regarding their survival distri-
butions. Considering that survival times are not nor-
mally distributed and because some survival times will
be censored by mortality, the Cox proportional-hazards
model will be used to analyze the data. Significance will
be expressed by the standard log rank test.
The effect of preventive nebulization on the primary
outcome will also be investigated in prespecified sub-
groups based on patient categories (namely, patients
with pneumonia versus patients without pneumonia and
surgical versus medical admissions), and will be adjusted
for the type of nebulizer (jet nebulizer or vibrating
mesh), humidification method (active or passive), and
type of flow used for nebulization (continues with exter-
nal source or breath synchronized with an inline flow
from the ventilator).
General statistical considerations
Initial analyses will be performed according to the
intention-to-treat (ITT) method. In addition, per-
protocol (PP) analysis, including only those patients
who complete the treatment according to the originally
allocated protocol, will be done to check for the ro-
bustness of the results.
Continuous normally distributed variables will be
expressed by their mean and standard deviation, or whennot normally distributed as medians and their interquartile
ranges. Categorical variables will be expressed as counts (n)
and percentages (%). To analyze differences in continuous
variables between the two groups, Student’s t-test will be
used, or in case continuous data is not normally distributed,
the Mann–Whitney U test will be used. Categorical vari-
ables will be compared with the Chi-square test or Fisher's
exact tests. Statistical significance is considered to be at a P
value <0.05 with one or two side test, depending on assess-
ment of either non inferiority or superiority. The ICU mor-
tality, hospital mortality, the length of ICU stay, and the
length of hospital stay will be expressed with Kaplan-Meier
curves.
When appropriate, statistical uncertainty will be
expressed by 95 % confidence levels. All statistical ana-
lyses will be performed with the R language and environ-
ment for statistical computing [53].
Economic evaluation
Alongside the proposed RCT, a prospective economic
study will be performed. The main question in the eco-
nomic evaluation is whether the beneficial effects of pre-
ventive nebulization, compared to nebulization on
indication, justifies the healthcare costs of preventive
nebulization. This analysis is set up as a cost-benefit
analysis (CBA), incorporating costs that will be esti-
mated from a health system perspective over the time
horizon of this study. In this economic evaluation, costs
will be determined for both randomization groups dur-
ing a 28-days follow-up period after ICU admission and
start of mechanical ventilation. The costs of medical care
will be calculated, divided into direct medical, direct
nonmedical, and indirect costs, if applicable. Costs are
defined as the volumes of used resources multiplied by
the calculated unit prices. No discounting of costs and
effects will be applied. Although, if any difference of
interest in primary and/or secondary outcomes is ob-
served, registered resource use and related costs will be
compared between both intervention groups. In addition
a cost-effectiveness analysis, to calculate incremental
cost ratios (ICER), will be performed.
Study organization
Trial oversight will be provided by a Trial Steering
Committee composed of the principal investigators, the
coordinating investigator and local investigators in the
participating centers. The principal investigators and
the trial coordinator are responsible for daily manage-
ment of the trial. They provide assistance to the partici-
pating sites in trial management, record keeping, data
management and training of the local staff. Local inves-
tigators in each site will perform randomization,
supervise data collection and ensure adherence to the
ICH-GCP guidelines during the trial.
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All data are coded by a patient identification number
(PIN). The key is kept at the trial sites in a secure
place. The data are transcribed by the local investiga-
tor into a central GCP-proof internet-based electronic
CRF. Recorded data, provided with a code, will be
stored securely for 15 years in archives of the Aca-
demic Medical Center, Amsterdam, The Netherlands.
Data will be accessible only by the principal investiga-
tors and representatives of the Inspectorate for
Healthcare of The Netherlands.
Monitoring, safety and the reporting of adverse events
An independent GCP-certified monitor will monitor
the study for data quality according to the ICH-GCP
guidelines. During onsite visits, monitoring will be
conducted on the following: progress of the study,
rights and wellbeing of the subjects, completeness
and accuracy of the recorded data, verifiability of the
recorded data from source documents, compliance
with the approved protocol and amendments, and
compliance with GCP and applicable national regula-
tory requirements. Every participating center will be
visited at least once every year.
Monitoring of patient safety and reviews of safety
issues will be performed by a designated independent
DSMB. The DSMB, consisting of three experts of
critical care and mechanical ventilation and an inde-
pendent statistician, watches over the ethics of the
conduct of the study in accordance with the Declar-
ation of Helsinki. The DSMB will meet by conference
calls. Meetings are scheduled prior to the first patient
enrolment, after inclusion of respectively 317 and 634
patients when the interim analyses for safety are per-
formed, and after completion of patient enrolment.
As the study population consists of critically ill pa-
tients, we expect many of the patients to develop ser-
ious adverse events according to the GCP guidelines’
definition. Serious adverse events (SAEs) considered
(possibly) related to the study procedure according to
the local investigator will be reported to the study co-
ordinator, SAE manager and principal investigator
within 24 hours. If at least one or both (that is, the
SAE manager and/or principal investigator) judges the
association with the study intervention as (possibly)
related, the SAE is classified as (possibly) related and
reported to the reviewing Institutional Review Board
and DSMB within 15 days. All (S)AEs will be pro-
vided to the reviewing Institutional Review Board and
DSMB in a line listing format every 6 months. If
complications occur significantly more often in the
intervention group, termination of the study due to
harm can be considered by the DSMB. Should the
principal investigator decide not to fully implementthe advice of the DSMB, the principal investigator
will send the advice to the reviewing Institutional Re-
view Board, including a note to substantiate why (part
of ) the advice of the DSMB will not be followed.
Discussion
Mechanical ventilation is associated with an impaired clear-
ance and retention of airway secretions, which can lead to
airway obstruction, atelectasis, bacterial colonization and
pulmonary infection [2, 7, 54]. Preventive nebulization of
mucolytic agents and bronchodilating drugs is a strategy
suggested to prevent these complications [2, 4, 7]. No previ-
ous studies have addressed whether this preventive strategy
is effective in a general ICU population of intubated and
ventilated ICU patients.
NEBULAE is the first randomized controlled trial
sufficiently powered to investigate the effectiveness,
safety and costs of preventive nebulization of muco-
lytic agents and bronchodilating drugs compared to
nebulization on indication.
All patients with an expected duration of ventilation
of more than 24 hours are eligible for inclusion. Patients
are excluded if they are admitted and invasively venti-
lated in another hospital before admission to be able to
determine the total duration of ventilation and guaran-
tee recording of all episodes of nebulization.
A concern regarding safety could be the occurrence
of endotracheal tube occlusion, although nebulization of
acetylcysteine is allowed in both groups in case of thick and
tenacious pulmonary secretions. Furthermore, nebulization
of liquids and solutions may cause obstruction and mal-
function of the expiratory valve due to deposition of the
aerosolized medication. To minimize this risk, awareness
and training about this risk among nurses and physicians is
advocated. Thereby, filters will be used and changed daily
to protect the ventilator. An interim analysis on safety will
be performed to evaluate these concerns. Furthermore,
sedation practice could mask potential patient discomfort
caused by the intervention. Similar sedation aims in both
arms of the trial need to be persuaded.
The main strength of this study is the potential
generalizability of its findings, considering the participation
of different types of ICU’s in several hospitals as well as the
broad spectrum of patients being eligible for participation.
Besides the intervention under study, which is a well-
known procedure familiar to nurses and physicians in all
participating centers, no additional measurements or pro-
cedures are part of the study protocol. Therefore, execution
of the study is straightforward and feasible.
This trial also has some weaknesses: first, due to the na-
ture of the intervention, blinding of patients and caregivers
is not possible. Acetylcysteine has a very typical odor that
cannot be mimicked, and consequently, nebulization with
saline as placebo is not possible. Investigators who perform
van der Hoeven et al. Trials  (2015) 16:389 Page 8 of 10the analyses however are blinded for the intervention. In
addition, the weaning process that directly, influences the
primary outcome, as well as the airway care, will be per-
formed by the attending ICU physician and nurse not
involved in this study. Second, despite the fact that in-
dications for nebulization of mucolytic agents or
bronchodilating drugs in the ‘the preventive nebuliza-
tion arm’ are set in the study protocol, indications are
known to be highly interpretable. Third, as this is a
multicenter study, differences in standard practice be-
tween participating centers exist. The study protocol,
however, stresses that standard care be performed ac-
cording to internationally accepted guidelines. More-
over, the randomization to both study arms is stratified
per center.
Participating centers are allowed to administer humidifi-
cation according to their local standard practice. Nebuliza-
tion of mucolytic agents and bronchodilating drugs will be
applied using either a jet nebulizer, the most commonly
used type of nebulizer [13] or a vibrating mesh nebulizer.
The type of nebulizer, as well as the type of humidification,
are suggested to influence the fraction of nebulized medica-
tion reaching the lung [55, 56]. As a consequence, uniform-
ity of the studied intervention might be diminished. This
choice was made since we aim to study current nebuliza-
tion practice and intent to avoid additional risks by intro-
ducing a new procedure with potential serious adverse
outcomes. To control for these factors, randomization is
stratified per center. In addition, data on applied care and
on the use of relevant concomitant strategies possibly in-
fluencing outcomes are collected. Also, prespecified sub-
group analyses are performed.
In conclusion, the NEBULAE trial investigates the ef-
fectiveness, safety and health-related costs of preventive
nebulization of mucolytic agents and bronchodilating
drugs compared to nebulization of mycolitic agents and/
or bronchodilating drugs on indication only, in intubated
and ventilated ICU patients, with regard to the number
of ventilator-free days and survival to day 28. Results of
this trial will guide local and international practice
guidelines regarding care for the invasively ventilated
patient.
Trial status
Patient recruitment for the NEBULAE trial is currently
ongoing in seven Dutch hospitals. Enrollment started on
22 July 2014. The anticipated recruitment completion
day is 1 June 2016.
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